HLA-G and single nucleotide polymorphism (SNP) associations with cancer in African populations: Implications in personal medicine

Adolf, Ismael; Almars, Amany I.; Dharsee, Nazima; Mselle, Teddy; Akan, Gökçe; Nguma, Irene Jeremiah; Nateri, Abdolrahman S.; Atalar, Fatmahan

doi:10.1016/j.gendis.2021.06.004

Cited by 6 publications

(6 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Functions Of Hla-g In Diseasesmentioning

confidence: 99%

“…It has been reported that the expression of HLA-G polymorphic variants could be associated with susceptibility to different diseases [ 26 , 27 ]. Figure 2 shows some correlations between HLA-G expression and several disorders especially cancers [ 1 , 12 , 19 , 21 , 24 , 26 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 ]. Furthermore, the expression of HLA-G has been described in several infectious diseases caused by bacterial, viral, or parasitic agents ( Table 1 ) [ 16 , 38 , 39 ].…”

Section: Functions Of Hla-g In Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Immunomodulatory Potential of Non-Classical HLA-G in Infections including COVID-19 and Parasitic Diseases

et al. 2022

View full text Add to dashboard Cite

Human Leukocyte Antigen-G (HLA-G), a polymorphic non-classical HLA (HLA-Ib) with immune-regulatory properties in cancers and infectious diseases, presents both membrane-bound and soluble (sHLA-G) isoforms. Polymorphism has implications in host responses to pathogen infections and in pathogenesis. Differential expression patterns of HLA-G/sHLA-G or its polymorphism seem to be related to different pathological conditions, potentially acting as a disease progression biomarker. Pathogen antigens might be involved in the regulation of both membrane-bound and sHLA-G levels and impact immune responses during co-infections. The upregulation of HLA-G in viral and bacterial infections induce tolerance to infection. Recently, sHLA-G was found useful to identify the prognosis of Coronavirus disease 2019 (COVID-19) among patients and it was observed that the high levels of sHLA-G are associated with worse prognosis. The use of pathogens, such as Plasmodium falciparum, as immune modulators for other infections could be extended for the modulation of membrane-bound HLA-G in COVID-19-infected tissues. Overall, such information might open new avenues concerning the effect of some pathogens such as parasites in decreasing the expression level of HLA-G to restrict pathogenesis in some infections or to influence the immune responses after vaccination among others.

show abstract

Section: Functions Of Hla-g In Diseasesmentioning

confidence: 99%

Section: Functions Of Hla-g In Diseasesmentioning

confidence: 99%

Immunomodulatory Potential of Non-Classical HLA-G in Infections including COVID-19 and Parasitic Diseases

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Genetic mutagenesis can be caused by DNA alterations under environmental or endogenous carcinogens, leading to carcinogenesis ( 39 ). Single nucleotide polymorphisms (SNPs) are proposed to be one of the important biomarkers in the prognosis and therapeutic response of oncologic patients ( 40 ). In this comprehensive review, there were three studies ( Table 2 ) reporting the association between ERCC1 polymorphisms and the risk of cervical cancer.…”

Section: Ercc1 In Cervical Cancermentioning

confidence: 99%

Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Cervical cancer is a public health problem of extensive clinical importance. Excision repair cross-complementation group 1 (ERCC1) was found to be a promising biomarker of cervical cancer over the years. At present, there is no relevant review article that summarizes such evidence. In this review, nineteen eligible studies were included for evaluation and data extraction. Based on the data from clinical and experimental studies, ERCC1 plays a key role in the progression of carcinoma of the uterine cervix and the therapeutic response of chemoradiotherapy. The majority of the included studies (13/19, 68%) suggested that ERCC1 played a pro-oncogenic role in both early-stage and advanced cervical cancer. High expression of ERCC1 was found to be associated with the poor survival rates of the patients. ERCC1 polymorphism analyses demonstrated that ERCC1 might be a useful tool for predicting the risk of cervical cancer and the treatment-related toxicities. Experimental studies indicated that the biological effects exerted by ERCC1 in cervical cancer might be mediated by its associated genes and affected signaling pathways (i.e., XPF, TUBB3, and. To move towards clinical applications by targeting ERCC1 in cervical cancer, more clinical, in-vitro, and in-vivo investigations are still warranted in the future.

show abstract

“…However, it is proposed that HLA-G expression on tumor B cells, as in Hodgkin lymphoma, may be potentially beneficial in controlling tumor cell proliferation, as in vitro HLA-G binding to ILT2 on B cell surface has been shown to cause inhibition of B cell proliferation, differentiation and antibody secretion [ 41 ]. In addition to its physiological role in maternal-fetal tolerance, HLA-G is commonly expressed by solid tumors and has been associated with poorer prognosis in several cancers [ 108 , 109 ], including HCC [ 110 , 111 , 112 ]. HLA-G expression has been reported in approximately 50% of primary HCC lesions, reaching 71% in advanced stage III disease.…”

Section: Non-classical Hla Class I Molecules (Hla-ib)mentioning

confidence: 99%

“…[41]. In addition to its physiological role in maternal-fetal tolerance, HLA-G is commonly expressed by solid tumors and has been associated with poorer prognosis in several cancers [108,109], including HCC [110][111][112]. HLA-G expression has been reported in approximately 50% of primary HCC lesions, reaching 71% in advanced stage III disease.…”

Section: Non-classical Hla Class I Molecules (Hla-ib)mentioning

confidence: 99%

Non-Classical HLA Class 1b and Hepatocellular Carcinoma

Tornesello

Racanelli

et al. 2023

Biomedicines

View full text Add to dashboard Cite

A number of studies are underway to gain a better understanding of the role of immunity in the pathogenesis of hepatocellular carcinoma and to identify subgroups of individuals who may benefit the most from systemic therapy according to the etiology of their tumor. Human leukocyte antigens play a key role in antigen presentation to T cells. This is fundamental to the host’s defense against pathogens and tumor cells. In addition, HLA-specific interactions with innate lymphoid cell receptors, such those present on natural killer cells and innate lymphoid cell type 2, have been shown to be important activators of immune function in the context of several liver diseases. More recent studies have highlighted the key role of members of the non-classical HLA-Ib and the transcript adjacent to the HLA-F locus, FAT10, in hepatocarcinoma. The present review analyzes the major contribution of these molecules to hepatic viral infection and hepatocellular prognosis. Particular attention has been paid to the association of natural killer and Vδ2 T-cell activation, mediated by specific HLA class Ib molecules, with risk assessment and novel treatment strategies to improve immunotherapy in HCC.

show abstract

HLA-G and single nucleotide polymorphism (SNP) associations with cancer in African populations: Implications in personal medicine

Cited by 6 publications

References 123 publications

Immunomodulatory Potential of Non-Classical HLA-G in Infections including COVID-19 and Parasitic Diseases

Immunomodulatory Potential of Non-Classical HLA-G in Infections including COVID-19 and Parasitic Diseases

Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications

Non-Classical HLA Class 1b and Hepatocellular Carcinoma

Contact Info

Product

Resources

About